Funding round
Vivid Dx raises $15M seed round
Vivid Dx (United Kingdom) has raised $15M in a seed round, announced on July 28, 2026. The company is Precision diagnostics company using AI and Raman spectroscopy to detect pathogens and test antimicrobial resistance. The round was led by Oxford Science Enterprises, with participation from Cedars-Sinai Intellectual Property Co., Jameel Investment Management Company.
Vivid Dx raised $15M in seed funding to advance its pathogen detection platform and appointed Keith O'Neill as CEO to lead clinical validation and commercialization.
Company
Vivid Dx
Amount
$15M (~$15M)
Round
Seed
Sector
Precision Diagnostics
Country
United Kingdom
Announced
July 28, 2026
Track every raise, every day
This deal appeared in The Daily Raise, July 28, 2026. Get the next edition in your inbox.
Just raised too?
Turn your funding news into guaranteed media coverage while the momentum lasts.